JWA
BBIO icon

JFS Wealth Advisors’s BridgeBio Pharma BBIO Stock Holding History

JFS Wealth Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.1K Buy
136
+10
+8% +$700 ﹤0.01% 1001
2026
Q1 		$9.36K Hold
126
– – ﹤0.01% 973
2025
Q4 		$9.64K Buy
126
+55
+77% +$3.61K ﹤0.01% 994
2025
Q3 		$3.69K Buy
71
+17
+31% +$829 ﹤0.01% 1233
2025
Q2 		$2.33K Sell
54
-35
-39% -$1.27K ﹤0.01% 1353
2025
Q1 		$3.08K Buy
89
+48
+117% +$1.62K ﹤0.01% 1311
2024
Q4 		$1.13K Sell
41
-38
-48% -$982 ﹤0.01% 1651
2024
Q3 		$2.01K Hold
79
– – ﹤0.01% 1488
2024
Q2 		$2K Buy
79
+19
+32% +$519 ﹤0.01% 1429
2024
Q1 		$1.86K Hold
60
– – ﹤0.01% 1474
2023
Q4 		$2.42K Buy
60
+21
+54% +$631 ﹤0.01% 1346
2023
Q3 		$1.03K Buy
39
+3
+8% +$85 ﹤0.01% 1588
2023
Q2 		$620 Buy
36
+8
+29% +$120 ﹤0.01% 1716
2023
Q1 		$465 Buy
28
+5
+22% +$58 ﹤0.01% 1729
2022
Q4 		$175 Sell
23
-7
-23% -$67 ﹤0.01% 1840
2022
Q3 		$0 Buy
30
+16
+114% +$166 ﹤0.01% 1739
2022
Q2 		$0 Sell
14
-1
-7% -$8 ﹤0.01% 1737
2022
Q1 		$0 Sell
15
-10
-40% -$103 ﹤0.01% 1820
2021
Q4 		$0 Buy
+25
New +$1.06K ﹤0.01% 1713

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

JFS Wealth Advisors's BBIO Position: Q2 2026 in Review

JFS Wealth Advisors increased its BridgeBio Pharma (BBIO) stake by 7.9% in Q2 2026, buying an estimated $700 and bringing the position to 136 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1001.

JFS Wealth Advisors first reported a position in BBIO in Q4 2021 and has held it in 19 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • JFS Wealth Advisors held 136 shares of BridgeBio Pharma worth $10.1K as of Q2 2026.
  • JFS Wealth Advisors bought 10 BridgeBio Pharma shares in Q2 2026, an estimated $700.
  • BridgeBio Pharma made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #1001 holding.
  • JFS Wealth Advisors first reported a position in BridgeBio Pharma in Q4 2021 and has held it in 19 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.